[SY23] シンポジウム 23　Encyclopedic Seamless Drug Development for Organ Agnostic Oncology Precision Medicine - Frontline therapeutics of targeting BRCA（HRD）, PARP, HER2 and NTRK genetic alteration -
【E】

[SY23-4] Tumor Agnostic Development, An Industry Perspective

^○David Hyman (Department of Loxo Oncology and Lilly Oncology, Loxo Oncology at Eli Lilly)